Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
CA266-0001
Non-small Cell Lung Cancer (NSCLC) Phase III
- 15 weeks
- 1st site activated in Canada
CA266-0003
Colorectal Cancer Phase II/III
- 9.6 weeks
- Canadian FPI
CA266-0003
Colorectal Cancer Phase II/III
- 7.8 weeks
CA266-0003
Colorectal Cancer Phase II/III
- 10.2 weeks
CEREN-3
ORL Phase III
- 10.4 weeks
- 1st site activated in Canada and Canadian FPI
CHJB647A12103
Chronic heart failure Phase Ib
- 10.6 weeks
CHTT227A12301
Huntington's Disease (Neurology) Phase III
- 8 weeks
- 2nd site activated worldwide and 1st site activated in Canada
CHTT227A12301
Huntington's Disease (Neurology) Phase III
- 9.6 weeks
D8456C00001
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Phase IIb
- 12 weeks
- 3rd site activated worldwide
D8820C00003 (PRISM)
C. difficile Phase IIb
- 7 weeks
D8820C00003 (PRISM)
C. difficile Phase IIb
- 10.8 weeks
EFC17905
Hemophilia Phase III
- 10.4 weeks
- 1st site activated in Canada
WO46069
Breast Cancer Phase II/III
- 9.4 weeks
- 1st site activated in Canada
WO46069
Breast Cancer Phase II/III
- 8.8 weeks
WO46069
Breast Cancer Phase II/III
- 8 weeks
1245-0256
Nephrology (Chronic kidney disease) Phase III
- 9 weeks
- 1st site activated in Canada
1493-0002
Idiopathic Pulmonary Fibrosis Phase IIa
- 15.6 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 6.4 weeks
20210181 (MARITIME-1)
Obesity Phase III
- 8.2 weeks